Get the Stockscreener App
176.45
0.08%
0.14
Pre-market:
177.50
1.05
+0.60%
Guardant Health Inc stock is traded at $176.45, with a volume of 2.57M.
It is up +0.08% in the last 24 hours and up +8.13% over the past month.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$176.31
Open:
$174.05
24h Volume:
2.57M
Relative Volume:
1.04
Market Cap:
$23.68B
Revenue:
$1.08B
Net Income/Loss:
$-433.19M
P/E Ratio:
-51.89
EPS:
-3.4004
Net Cash Flow:
$-225.09M
1W Performance:
-3.63%
1M Performance:
+8.13%
6M Performance:
+111.09%
1Y Performance:
+205.96%
1-Day Range:
$173.50
$181.79
1-Week Range:
$170.50
$183.50
52-Week Range:
$58.73
$183.51
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
176.45 | 23.68B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
678.39 | 250.83B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
223.77 | 157.31B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
408.79 | 58.92B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
172.84 | 48.73B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
275.02 | 45.27B | 16.63B | 1.39B | 2.12B | 8.0674 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Reiterated | Canaccord Genuity | Buy |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Sep-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-22-25 | Resumed | Wells Fargo | Overweight |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Guardant Health, Inc. (GH) stock price, news, quote and history - Yahoo Finance Singapore
Guardant Health, Inc. (GH) Stock Price, News, Quote & History - Yahoo! Finance Canada
This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval - marketwatch.com
Form 4 Guardant Health Inc For: 22 September By Investing.com - Investing.com Canada
Guardant Health (GH) director adds 264 shares from RSU vesting - Stock Titan
Guardant Health Inc (GH) Shares Fall 3.1% -- What GF Score of 65 Tells Investors - GuruFocus
Tempus AI Fails to Trim Guardant Lawsuit Over Diagnostic Tests - Bloomberg Law News
Guardant Health, Inc. (GH) Stock Analysis: A Strong Buy With 9% Upside Potential - DirectorsTalk Interviews
Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening - The National Law Review
Guardant Health Director Steve E. Krognes Sells 6,674 Shares Between $174.46 and $177.48 - Kalkine Media
Barclays Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $200 - Moomoo
Guardant Health (GH) Lands First FDA Cleared Breast Cancer Liquid Biopsy Role - finance.yahoo.com
Director Steve Krognes Sells 6,674 Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health on Track for Record High Close -- Data Talk - Bitget
Cathie Wood’s ARK increases stake in Guardant Health stock - Investing.com
Guardant Health (GH) director plans new stock sale - Stock Titan
Guardant Health (NASDAQ: GH) director may sell $144K in equity-comp stock - stocktitan.net
Guardant Health (NASDAQ: GH) director moves to sell 6,674 shares - Stock Titan
Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH) - Yahoo Finance
Cathie Wood’s ARK buys Guardant Health stock, sells Iridium - Investing.com
Officer at Guardant Health (NASDAQ: GH) plans sale of 7,738 shares under Rule 144 - Stock Titan
Guardant Health stock hits 52-week high at 176.68 USD - Investing.com
Guardant Health (GH) Insider Sale: Chief Information Officer Kum - GuruFocus
Guardant Health CIO Kumud Kalia sells $632k in stock - Investing.com
Is Guardant Health Inc (GH) Overvalued After 6.6% Rally? GF Valu - GuruFocus
Guardant Health rises as investors weigh recent FDA approval, coverage expansion, and supportive analyst views - quiverquant.com
Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening - FinancialContent
Guardant Health, Inc. (GH) Stock Analysis: 24% Upside Potential Amid Strong Buy Ratings - DirectorsTalk Interviews
Guardant Health Inc Share PriceGH, RNS News, Articles, Quotes, & Charts - Proactive financial news
Guardant Health (NASDAQ: GH) officer moves to sell more stock - stocktitan.net
(GH) Volatility Zones as Tactical Triggers - Stock Traders Daily
Bernstein reiterates Guardant Health stock rating on margin outlook - Investing.com
Bernstein reiterates Guardant Health stock rating on margin outlook By Investing.com - Investing.com Canada
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer - BioSpace
GH Maintained by UBS -- Price Target Raised to $225 - GuruFocus
Guardant Health and Collaborators Present 20 Abstracts Showcasing Advances in Liquid Biopsy Tests and Methylation-Based Tumor Classification for Lung Cancer At 2026 World Conference on Lung Cancer - marketscreener.com
UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating - finance.yahoo.com
symbol__ Stock Quote Price and Forecast - CNN
GH Initiates Coverage On Guardant Health -- Buy Rating by Rothsc - GuruFocus
Business Insider Names Guardant Health One of America's Most Innovative Businesses - Business Wire
What Makes Guardant Health (GH) a Compelling Bet? - Yahoo Finance
Rothschild Redburn initiates Guardant Health stock with buy rating By Investing.com - Investing.com Canada
Rothschild Redburn initiates Guardant Health stock with buy rating - investing.com
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah - Zacks Investment Research
Guardant Health, Inc. (GH) Stock Analysis: Unveiling a 20% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Guardant Health Leads the Way in Blood-Based Single Cancer Screening - Morningstar
Guardant Health Stock Price Forecast. Should You Buy GH? - StockInvest.us
GH Looks 144.6% Overvalued on GF Value™ - GuruFocus
Guardant Health Faces a $245 Million Patent Judgment, But Its Newer Tests Could Offer Protection - Yahoo Finance
Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer - Yahoo Finance
AstraZeneca Breast Cancer Drug Etcamah Nets Accelerated FDA Approval With Guardant Health ctDNA Test - GenomeWeb
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):